67TH ASH Annual Meeting & Expo

Key Presentations

Title: Single-Cell Multiomics Enables Superior MRD Detection and Therapeutic Insight in Myeloid Malignancies

Date: Sunday, December 7th, 1:30pm EST

Where: Booth 2129

Who: Adam Sciambi, Chief Technology Officer, Co-Founder

Abstract:

The ability to sensitively detect measurable residual disease (MRD) and to understand the biology of therapy-resistant clones is central to both patient management in myeloid malignancies and the development of more effective targeted therapies. Standard MRD methods and bulk assays often miss rare leukemic subpopulations or misclassify benign clonal hematopoiesis, limiting their value for relapse prediction, risk stratification, and therapeutic decision-making.

Single-cell multiomic profiling overcomes these limitations by simultaneously capturing genotype and phenotype at single-cell resolution. Across multiple clinical settings, this approach outperforms conventional assays by detecting residual leukemic clones with higher sensitivity and specificity and by correctly distinguishing them from non-leukemic or preleukemic populations. It also reveals co-mutant subclones, clonal hierarchies, and phenotypically distinct populations that are routinely missed by bulk sequencing or flow cytometry.

These high-resolution insights not only improve MRD assessment but also illuminate mechanisms of action, define biomarker-driven subgroups, and identify resistant or target-dependent cell populations relevant to therapeutic development. Together, single-cell multiomics provides a unified framework that strengthens both relapse monitoring and precision drug development in myeloid malignancies.

Oral Presentations

280 - Clinical translation of single cell measurable residual disease (scMRD) assay in real world Acute Myeloid Leukemia (AML) patients

Date: Saturday, December 6, 02:45 PM - 03:00 PM EST

Part of session: 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: MRD Assays and Novel Drug Discovery Pipelines

Room: Hyatt - Regency Ballroom R

Katarina Micin, BS, MS, University of Miami

71 - Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells

Date: Saturday, December 6, 10:30 AM - 10:45 AM EST

Part of session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Precision targeting in MPN

Room: OCCC - W414AB

Bethan Psaila, University of Oxford, Incyte

77 - Molecular landscape and clonal evolution in minor versus major BCR::ABL1 chronic myeloid leukemia under tyrosine kinase inhibition : A Study from the french group fi-LMC

Date: Saturday, December 6, 10:30 AM - 10:45 AM EST

Part of session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Decoding the Molecular Drivers of response and resistance

Room: OCCC - Valencia Room W415D

Benjamin Podvin, University of Lille, Canther, Inserm

333 - Immunoglobulin variable gene diversity reflects distinct metabolic/signaling states and impacts measurable residual disease monitoring and clinical outcome in B cell acute lymphoblastic leukemia

Date: Saturday, December 6, 04:30 PM - 04:45 PM EST

Part of session: 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Critical biomarkers and classifiers in B-ALL and T-ALL ontogeny and outcomes

Room: OCCC - W224CDGH

Carol Fries Simpson, University of Rochester

348 - Multi-omic single cell sequencing reveals discordant MRD and mechanisms of relapse in pediatric AML

Date: Saturday, December 6, 05:15 PM - 05:30 PM EST

Part of session: 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: From Detection to Decision: MRD as the Compass in AML

Room: OCCC - Valencia Room W415A

Cheryl Peretz, MD, UCSF

484 - Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Date: Sunday, December 7, 10:15 AM - 10:30 AM EST

Part of session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Between a Rock and a Ropeg - Innovative Therapies for MPNs

Room: OCCC - W414AB

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, Incyte

1024 - Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Date: Monday, December 8, 05:15 PM - 05:30 PM EST

Part of session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Drivers and Mast Cells and Blasts, Oh My! - Insights and Treatments for MPNs and Mastocytosis.

Room: OCCC - West Hall D2

Vikas Gupta, MD FRCP, FRCPath, Princess Margaret Cancer Centre, Incyte